文献速递乳腺癌放疗放疗物理与技术

早期乳腺癌立体定向加速部分乳腺照射后的美容效果与毒性:一项前瞻性观察性队列研究

Cosmetic Outcome and Toxicity After Stereotactic Accelerated Partial Breast Irradiation in Early Breast Cancer: A Prospective Observational Cohort Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-05-17

这项前瞻性观察性队列研究纳入204例乳腺癌患者(APBI组103例,WBI组101例),APBI采用射波刀M6机器人放射外科系统给予30 Gy分5次非连续每日照射。APBI组患者报告6个月皮肤干燥、放射性皮肤反应和乳房硬度均显著少于WBI组,医生评估12个月皮炎显著少于WBI组;APBI组24个月美容效果优良率为77.6%,较基线无显著美容损害。

要点

  • APBI组6个月患者报告皮肤干燥6.9% vs WBI组18.3%(P=.015),放射性皮肤反应9.9% vs 23.5%(P=.010),乳房硬度8.0% vs 20.4%(P=.011)。
  • APBI组医生评估12个月皮炎1.0% vs WBI组7.2%(P=.027)。
  • APBI组24个月美容效果优良率77.6%,较基线无显著美容损害。

核心结论

  • 立体定向APBI与WBI相比,未受累乳腺象限的纤维化更少。
  • APBI患者毒性轻微,且对美容效果无不良影响。

研究设计与样本

  • 前瞻性观察性队列研究,纳入接受APBI的乳腺浸润癌或原位癌女性患者,同时纳入接受WBI的女性作为对照。
  • APBI使用射波刀M6机器人放射外科系统,剂量为30 Gy分5次非连续每日照射。
  • 共纳入204例患者,其中APBI组103例,WBI组101例;按研究方案随访至治疗后24个月。

主要发现

  • 患者报告结局:APBI组6个月皮肤干燥6.9% vs WBI组18.3%(P=.015),放射性皮肤反应9.9% vs 23.5%(P=.010),乳房硬度8.0% vs 20.4%(P=.011)。
  • 医生评估:APBI组12个月皮炎1.0% vs WBI组7.2%(P=.027)。
  • APBI后严重毒性罕见:患者报告结局评分≥3为3.0%,医生评估分级≥3为2.0%。
  • 未受累象限测得纤维化:APBI组在6个月(P=.001)和12个月(P=.029)显著低于WBI组,24个月时无显著差异;受累象限测得纤维化在各时间点两组均无显著差异。
  • APBI组24个月美容效果多为优良(77.6%),且较基线无显著美容损害。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this work was to prospectively evaluate the toxicity and cosmetic outcomes of 5-fraction, stereotactic, accelerated partial breast irradiation (APBI). METHODS AND MATERIALS: This prospective observational cohort study enrolled women who underwent APBI for invasive carcinoma or carcinoma in situ of the breast. APBI was delivered using a CyberKnife M6 robotic radiosurgery system at 30 Gy in 5 nonconsecutive, once-daily fractions. Women undergoing whole breast irradiation (WBI) were also enrolled for comparison. Patient-reported and physician-assessed adverse events were recorded. Breast fibrosis was measured using a tissue compliance meter, and breast cosmesis was assessed using BCCT.core (an automatic, computer-based software). Outcomes were collected until 24 months posttreatment according to the study protocol. RESULTS: In total, 204 patients (APBI, n = 103; WBI, n = 101) were enrolled. Regarding patient-reported outcomes, the APBI group reported significantly less skin dryness (6.9% vs 18.3%; P = .015), radiation skin reaction (9.9% vs 23.5%; P = .010), and breast hardness (8.0% vs 20.4%; P = .011) at 6 months than the WBI group. On physician assessment, the APBI group had significantly less dermatitis at 12 months (1.0% vs 7.2%; P = .027) than the WBI group. Any severe toxicities after APBI were rare in patient-reported outcomes (score ≥3, 3.0%) and physician assessments (grade ≥3, 2.0%). In the uninvolved quadrants, measured fibrosis in the APBI group was significantly lower than that in the WBI group at 6 (P = .001) and 12 (P = .029) months but not at 24 months. In the involved quadrant, measured fibrosis in the APBI group was not significantly different from that in the WBI group at any time. Cosmetic outcomes in the APBI group were mostly excellent or good (77.6%) at 24 months, and there was no significant cosmetic detriment from the baseline. CONCLUSIONS: Stereotactic APBI was associated with less fibrosis in the uninvolved breast quadrants than WBI. Patients showed minimal toxicity and no detrimental effects on cosmesis after APBI.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Byun HK, Chang JS, Kim H, et al. Cosmetic Outcome and Toxicity After Stereotactic Accelerated Partial Breast Irradiation in Early Breast Cancer: A Prospective Observational Cohort Study. Int J Radiat Oncol Biol Phys. 2023. PMID: 37201757. doi:10.1016/j.ijrobp.2023.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。